Methylphenidate for Attention in Sickle Cell Disease
Part of Blood & lymphatic, Genetic & congenital, Mental health clinical trials.
This trial tests if a medication called methylphenidate can help children with sickle cell disease who have trouble with attention, focus, or executive function. It aims to see if it can improve daily life and school performance.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 8 and 17 years old.
- You have been diagnosed with sickle cell disease.
- You have attention or focus difficulties, such as low scores on thinking tests or a diagnosis of ADHD.
- You speak English as your main language.
- You are willing to take part with a parent or guardian.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a program to help preschoolers with sickle cell disease get ready for school. It looks at whether a special learning program can help with skills like paying attention and getting along with others.
This trial tests whether a computer-based “attention control” training program can improve attention and daily functioning in children with sickle cell disease. To join, you must meet certain criteria and also pass an initial attention screening test during the study.
This trial is testing a digital program to help improve working memory (the ability to hold and use information in your mind) for children with sickle cell disease. If you join, you'll use a computer-based training program at home and researchers will see if it works and is easy to use.
This Phase 2 study tests a cognitive (thinking) training program to help teens with sickle cell disease prepare for the changes in their care as they grow older. It may help with skills like learning, attention, and planning for transition to adult care.
This trial tests starting a new medication (Methylphenidate or Guanfacine) in young children with moderate or severe ADHD to see how well it works and if it’s safe.
This trial tests a new treatment called CS-206 for adolescents with severe sickle cell disease. It aims to see if this treatment can help by making stem cell transplants safer and more effective for people who have not done well with standard care.
Hear when a new Sickle Cell Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.